BioCentury | Oct 24, 2019
Financial News

Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

...towards completing Phase III trials in the U.S and China for suicidal bipolar depression candidate NRX-101...
BioCentury | Jan 11, 2019
Clinical News

NeuroRx's NRX-101 improves depression and suicidality in Phase II

...NeuroRx Inc. (Wilmington, Del.) said NRX-101 improved depression and suicidality in the Phase II STABIL-B trial...
...December at the American Congress of Neuropsychopharmacology in Hollywood, Fla. In 15 evaluable patients, oral NRX-101...
...at day 14; Columbia Suicide-Severity Rating Scale (C-SSRS) Status: Phase II data Milestone: NA Chris Lieu Cyclurad (NRX-101) NeuroRx...
BioCentury | Jan 5, 2017
Clinical News

NRX-101: Ph IIb/III started

...NeuroRx began a double-blind Phase IIb/III trial to compare twice-daily oral NRX-101 containing 175 or 237.5...
...weeks in about 120 patients with bipolar depression. NeuroRx Inc. , Wilmington, Del. Product: NRX-101, Cyclurad...
...on series of psychometric scales Status: Phase IIb/III started Milestone: NA Julian Zhu Cyclurad NeuroRx Inc. NMDA receptor Serotonin (5-HT2A) receptor NRX-101...
Items per page:
1 - 3 of 3